Developing new cardiac regeneration therapies
Improving heart failure and myocardial infarction outcomes through development of new cardiac regeneration therapies
Giving the Failing Heart the Nutrients it Needs
Understanding mechanisms underlying a type of “stiff” heart failure common in diabetics
A novel target in cardiovascular disease to predict how likely you are to suffer a heart attack or stroke
Translating genomics into improved care
Improving care of inherited heart disease and sudden death families through identification of new disease genes using state-of-the-art genetic approaches
Prevention of cardiovascular disease in the clinical context
Using mobile and digital health interventions to support patients after a heart attack modify their health behaviours
New markers and mechanisms of atherosclerosis
Discovering and translating new markers and mechanisms of atherosclerosis
Cardioprotective effects of the pneumococcal polysaccharide vaccine
Investigate whether pneumococcal polysaccharide vaccine lowers risk of heart attack and stroke
Reverse cholesterol transport in at risk populations
Investigating if at risk populations have reduced capacity to clear cholesterol from their body
High throughput assay for safety screening
Build and validate a screening workflow and accompanying software that can be incorporated into preclinical safety screening pipelines for more accurate allocation of cardiovascular safety liabilities and increase the output of new drugs to benefit patients
Translating genomics for inherited heart disease
Translate new genetic testing approaches for inherited heart diseases with higher diagnostic yield
Development of MultiStretcher platform
Application of an IsoStretcher biomechatronics platform and engineering of a novel parallelized MultiStretcher technology for studies of cardiac mechano-signaling in HL-1 and atrial cardiomyocytes
Pathogenicity of all missense variants in KCNH2
Determining the probability of pathogenicity of all missense variants in KCNH2, the genetic basis of congenital long QT syndrome type 2
Manipulation of the ageing endothelium
Developing new therapeutics directed towards the age-damaged endothelium
Extending the time for thrombolysis in emergency neurological deficits with tenecteplase (EXTEND TNK 24)
Pathophysiological mechanisms, new methodologies, improved diagnosis and new treatment
Develop and use state-of-the-art magnetic resonance imaging (MRI) to better understand, diagnose, and evaluate a new treatment heart failure
Dissecting molecular causation of hypoplastic left heart
Using patient-specific induced pluripotent stem cells to dissect molecular causation of hypoplastic left heart
Treatment of high risk unstable atherosclerotic plaque
Identification of vascular inflammation and treatment of high risk unstable atherosclerotic plaque
Precision medicine in congenital heart disease care
Working towards a genetic diagnosis for the majority and identifying the benefits
Epicardial coronary artery dissection
Better understanding, treating and preventing spontaneous coronary artery dissection by identifying factors that predispose the coronary artery to spontaneous tearing
Non-invasive device to monitor pregnancy and labour progression
System to enable evaluation of tear film problem
Implementation of an innovative re-usable respirator in healthcare for Pandemic
Digital therapeutic to engage and motivate patients to better manage their conditions and form healthy habits
Functional genomics capacity and capability
This initiative will see the establishment of a translational stem cell biology team and enhancements to existing infrastructure to support functional genomics capability. This will allow for the capacity for stem cell production, organoid and cell-based disease modelling and genetic modifications for applied genomics
Precision medicine utilises large data sets that combine omics with clinical information and health outcomes to optimize disease diagnosis, treatment and prevention specific to each patient
Predisposition screening for cancers
This program will see all children in NSW diagnosed with cancer eligible to participate in a genetic predisposition screening study. It will allow us to identify gene variants of possible clinical significance and to identify families susceptible to the development of cancer and rare diseases. This program will establish the foundation for access to the appropriate services for the management of risk, preventative measures and treatment for children and families with a genetic predisposition to cancer.
The Clinical Trials project will underpin the translational ambition of Luminesce Alliance by building capacity to offer novel drugs and gene therapies to children with genetic rare diseases and cancer, utilising innovative trial design including adaptive trials
Data integration – predictive analysis
This project involves the integration and linkage of genomic and clinical trials data with clinical and population based administrative health data. Such linkage and integration will provide a better understanding of the risk factors associated with rare diseases and cancer so that personalised treatment and prevention pathways can be developed
Economic impact and health implementation analysis of a model for cancer
Precision medicine is revolutionising healthcare and changing practice, this initiative will measure the benefits for families and the healthcare system to better inform policy; and, contribute to a sustainable implementation of precision models across a complex health system
Economic impact and health implementation analysis of a model for blinding genetic eye conditions
Monogenic retinal diseases can lead to progressive visual deterioration and blindness with a significant impact on children and young people. There are emerging genetic therapies aimed at saving vision in patients that would otherwise go blind. However, there is no research on the cost-effectiveness of ocular genomic testing in Australia. This new Luminesce Alliance project is designed to address the gap in economic evidence required to implement genomic medicine for patients with blinding retinal diseases in the Australian healthcare system
Psychosocial implications of paediatric precision medicine
The psychosocial implications of genetic testing and precision medicine for children and their families and the healthcare professionals who care for them
Supporting adults with chronic kidney disease
Supporting adults with Chronic Kidney Disease to engage in shared decision making successfully (SUCCESS): A pragmatic randomised controlled trial of the SUCCESS intervention
Improving detection, management and prevention of delirium to improve patient outcomes and staff competence
Partnerships in Aged-Care Emergency services using Interactive Telehealth (PACE-IT) incorporating telehealth visual assessment, information sharing and decision making for people living in residential aged-care facilities (RACF)
Reducing unplanned general surgical readmissions
Innovative approach to reducing surgical readmissions to improve outcomes, improve patient satisfaction and decrease cost
Virtual clinical pharmacy service
Realising the benefits of clinical pharmacy in the bush: the efficacy and scalability of a virtual clinical pharmacy service (VCPS) in rural and remote NSW health facilities
A randomised controlled trial of a comprehensive smartphone application-centric model of care to improve outcomes in patients with cardiovascular disease
Intervention to try to prevent infection by using gloves when staff touch babies in addition to the handwashing
Facilitating engagement between people in rural and remote NSW and their medical practitioners through a mix of telehealth and fly-in-fly-out care
Vaporised nicotine products for smoking cessation
A trial of the effectiveness of vaporised nicotine products (VNPs) for smoking cessation amongst NSW opiate agonist treatment (OAT) clients
Best practice for incontinence-associated dermatitis
A novel implementation of best available evidence into practice for incontinence-associated dermatitis (IMBED)
Endovascular treatment of peripheral artery disease
A novel biotechnology platform for endovascular treatment of peripheral artery disease